

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

MAR 23 2007

SHEET 1 OF 1

Application No.	10/553,078
Filing Date	June 23, 2006
First Named Inventor	Straten et al.
Art Unit	1643
Examiner	Anne Gussow
Attorney Docket No.	HOIB1.001APC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP.1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/AMG/	1	WO 01/44282 A2	06-21-2001	Reed et al.		
/AMG/	2	WO 02/072627 A2	09-19-2002	Wrede et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹

3532901
031407

Examiner Signature	/Anne Gussow/	Date Considered	06/26/2007
--------------------	---------------	-----------------	------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/553,078	
	PCT Application No.	PCT/DK2004/000259	
	Filing Date	April 7, 2004	
	First Named Inventor	Straten et al.	
	Art Unit	1615	
(Multiple sheets used when necessary)		Examiner	Unknown
SHEET 1 OF 2		Attorney Docket No.	HOIB1.001APC

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
/AMG/	1	WO 00/03693 A	01-27-2001	Jenner Biotherapies Inc.		
/AMG/	2	WO 00/77201 A	12-21-2000	Astrazeneca		
/AMG/	3	JP 2002 284797A	02-05-2003	Hokkaido Technology Licence Office Co Ltd		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/AMG/	4	ANDERSEN et al., "Identification of a Cytotoxic T Lymphocyte Response to the Apoptose Inhibitor Polypeptide Survivin in Cancer Patients," <u>Cancer Res.</u> 61, 869-872 (2001).	
	5	ANDERSON et al., "Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients," <u>Cancer Research</u> , American Association for Cancer Research, Baltimore, MD, USA, Vol. 61, No. 16 (August 15, 2001)	
	6	ANDERSON et al., "The melanoma inhibitor of apoptosis protein: A target for spontaneous cytotoxic T cell responses" <u>Journal of Investigative Dermatology</u> , Vol. 122, No. 2, (February 2004)	
	7	ASHHAB et al., "Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern" <u>FEBS Lett.</u> 20, 56-60 (2001).	
	8	BATTEGAY et al., "Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells," <u>J. Immunol.</u> 15, 5408-15 (1993).	
	9	BECKER et al., "Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells: induction of proliferation and cytokine production," <u>J. Invest. Dermatol.</u> 101, 15-21 (1993).	
	10	CORMIER et al., "Comparative analysis of the <i>in vivo</i> expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy," <u>J. Immunother.</u> 21, 27-31 (1998).	
	11	ENNIS et al., "Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines" <u>J. Gen. Virol.</u> 58, 5408-15 (1982).	
	12	HERR et al., "Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood," <u>Proc. Natl. Acad. Sci. U.S.A.</u> 96, 12033-12038 (1999).	
	13	HESLOP et al., "Adoptive cellular immunotherapy for EBV lymphoproliferative disease," <u>Immunol. Rev.</u> , 157, 217-222 (1997).	
↓	14	JAATTELA, M., "Escaping cell death: survival polypeptides in cancer," <u>Exp. Cell Res.</u> 248, 30-43 (1999).	
/AMG/	15	JAGER et al., "Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma" <u>Int. J. Cancer</u> 71, 142-147 (1997).	

Examiner Signature	/Anne Gussow/	Date Considered	06/26/2007
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/553,078	
	PCT Application No.	PCT/DK2004/000259	
	Filing Date	April 7, 2004	
	First Named Inventor	Straten et al.	
	Art Unit	1615	
(Multiple sheets used when necessary)		Examiner	Unknown
SHEET 2 OF 2		Attorney Docket No.	HOIB1.001APC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
/AMG/	16	KASOF et al., "Livin, a novel inhibitor of apoptosis polypeptide family member," <u>J. Biol. Chem.</u> 276, 3238-3246.	
	17	KESSLER et al., "Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides," <u>Hum. Immunol.</u> 64, 245-255 (2003).	
	18	KUBO et al., "Definition of specific peptide motifs for four major HLA-A alleles," <u>J. Immunol.</u> 152, 3913-3924 (1994).	
	19	MARCHAND et al., "Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1," <u>Int. J. Cancer</u> 80, 219-230 (1999).	
	20	MOUDGIL et al., "Can antitumor immune responses discriminate between self and nonself?" <u>Immunol. Today</u> 15, 353-355 (1994).	
	21	NESTLE et al., "Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells," <u>Nat. Med.</u> 4, 328-332 (1998).	
	22	PARKHURST et al., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp 100 modified at HLA-A*0201-binding residues" <u>J. Immunol.</u> 157, 2539-2548.	
	23	ROSENBERG et al., "Immunological and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," <u>Nat. Med.</u> 4, 321-327 (1998).	
	24	ROSENBERG, S.A., "Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens," <u>J. Natl. Cancer Inst.</u> 20, 1635-1644 (1996).	
	25	SCHEIBENBOGEN et al., "Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment," <u>Int. J. Cancer</u> 20, 409-414 (2002).	
	26	SCHMOLLINGER et al. "Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction," <u>Proceedings of the National Academy of Sciences of the U.S.A.</u> , Vol. 100, No. 6 (March 18, 2003)	
	27	THURNER et al., "Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma," <u>J. Exp. Med.</u> 190, 1669-1678 (1999).	
	28	VAN DEN EYNDE et al., "Tumor recognized by T lymphocytes," <u>Int. J. Clin. Lab. Res.</u> 27, 81-86 (1997).	
	29	VUCIC et al., "ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas," <u>Curr. Biol.</u> 10 1359-1366 (2000).	
	30	YEE et al., "Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo" <u>J. Exp. Med.</u> 192, 1637-1644 (2000).	
↓	31	YEWDELL et al., "Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses," <u>Annu. Rev. Immunol.</u> 17, 51-88 (1999).	
/AMG/	32	ZEH et al., "High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy" <u>J. Immunol.</u> , 162, 989-94 (1999).	

2287549/011606

Examiner Signature	/Anne Gussow/	Date Considered	06/26/2007
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>			

T¹ - Place a check mark in this area when an English language Translation is attached.